Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

PROgram To Enhance Cardiovascular Risk Trough an Intervention of Nutrition in Bipolar Disorder

NCT06488573 · tracked via the Priya Life Science Brazil tracker
Phase
Not applicable
Started
2026-04
Last updated
2026-03-02

Condition(s) studied

Bipolar DepressionBipolar Disorder (BD)

Investigational drug(s) / intervention(s)

Nutritional intervention

Nutritional intervention: 7 individual sessions (online) + 6 small group sessions (1-in person + 5 online)

Study summary

Individuals with Bipolar Disorder (BD) have twice the risk of being affected by metabolic comorbidities and a 1.8-fold increased risk of mortality from cardiovascular diseases when compared to the general population. These factors are fundamental in the 14-year reduction in the life expectancy of people with TB reported in recent meta-analyses. This occurs mainly due to the increased inflammation associated with the disease, the adverse effects of pharmacological treatments and unhealthy lifestyle habits that are more common in people diagnosed with BD. Nutrition has been studied as an adjunctive treatment in other psychiatric disorders, but there is a lack of studies about the role of nutrition in TB. Considering that diet can impact metabolic health, this randomized controlled study aims to evaluate the effect of a nutritional intervention on cardiovascular risk in patients with TB. The intervention is based on the dietary pattern recommended in the Dietary Guidelines for the Brazilian Population and will be applied by a registered dietitian. According to the literature, the sample size will be 72 individuals with TB (36 in the control group with usual treatment + 36 in the intervention group added to the usual treatment). The intervention will be carried out in 7 individual sessions and 8 group sessions with specific themes. The primary aim of this protocol will be an intervention to contribute to cardiovascular health - verified by serum markers, anthropometric measurements and the Framingham Cardiovascular Risk Score (algorithm used to estimate an individual's 10-year cardiovascular risk). The secondary stages will be the adherence of the intervention and the impact on the quality of life of the participants. The possible positive results of this nutritional intervention can open new clinical perspectives. Meaning that might show that better food choices can protect the cardiovascular health of individuals with TB, leading to a reduction in morbidity and mortality associated with the disease.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Clinical diagnosis of Bipolar disorder types I and II diagnosis * Adults of both genders, from 18 to 60 years old * In typical pharmacotherapy for BD, for at least one month * Agreement to participate in the study with signature of the consent form Exclusion Criteria: * Patients with "very good or excellent" diet quality assessed by the diet quality scale (ESQUADA): \>275 out of a score of 375 * Patients in a state of hypomania or mania: score \>8 (Young Mania Rating Scale - YMRS) * Patients with severe depression \>21 Montgomery-Åsberg Depression Rating Scale * Patients at low cardiovascular risk (\<7 points for men or \<9 points for women on the Framingham Global Risk Score) * Low weight or eutrophic body mass index: \<25kg/m² as in similar studies * Pregnant or breastfeeding women * Patients diagnosed with anorexia and bulimia nervosa * Patientes diagnosed with Irritable Bowl Syndrome or other diagnosed conditions that affect the gastrointestinal function

Primary outcome measure(s)

  • C reactive protein — Baseline, week 12, week 24 and follow up at week 52
    C reactive protein
  • Total cholesterol and fractions — Baseline, week 12, week 24 and follow up at week 52
    Total cholesterol and fractions
  • Glycemia — Baseline, week 12, week 24 and follow up at week 52
    Glycemia
  • Glycated hemoglobin A1C — Baseline, week 12, week 24 and follow up at week 52
    Glycated hemoglobin A1C
  • Triglycerides — Baseline, week 12, week 24 and follow up at week 52
    Triglycerides
  • HOMA IR — Baseline, week 12, week 24 and follow up at week 52
    HOME IR
  • Apoliporpotein B — Baseline, week 12, week 24 and follow up at week 52
    Apoliporpotein B
  • Cardiovascular risk — Baseline, week 12, week 24 and follow up at week 52
    Framingham Global Risk Score (-3 to 21; higher scores mean worse outcome)
  • Body weight — Baseline, week 12, week 24 and follow up at week 52
    Body weight
  • Body fat percentage — Baseline, week 12, week 24 and follow up at week 52
    Body fat percentage
  • waist circumference — Baseline, week 12, week 24 and follow up at week 52
    waist circumference

Trial sites (1)

FacilityCityRegionStatus
Fernanda Gabriel São Paulo São Paulo Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06488573 on ClinicalTrials.gov ↗ ← All trials in Brazil